Every 10-Q that MEDINOTEC INC (MDNC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow MDNC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MDNC filings page.
Medinotec Inc. reported higher quarterly revenue and profit for the three months ended May 31, 2026. Revenue rose to $2,651,095 from $2,134,026, while gross margin improved to 49% from 43%, lifting net income to $222,014 or $0.02 per share.
Operating income declined to $180,872 as selling expenses increased sharply due to distributor support costs in South Africa. Cash was $2,518,315 with minimal debt, but the company remains highly dependent on one South African distributor, which generated 87% of revenue.
Medinotec Inc. reported unaudited results for the quarter and nine months ended November 30, 2025. Nine‑month revenue rose to $7,907,325 from $5,588,445 a year earlier, with net income increasing to $863,761 from $682,264, or basic and diluted EPS of $0.07 versus $0.06. Quarterly revenue was $2,536,994 with net income of $403,411.
Gross profit for the nine‑month period grew to $4,273,556, while operating income reached $1,358,734. The company strengthened its balance sheet: cash was $2,856,926 and loans payable dropped sharply to $452 from $940,277 as of February 28, 2025, lifting total equity to $5,500,237. Operations outside the U.S. generated most revenue and profit.
Results remain highly concentrated, as approximately 92% of revenue for the nine months came from a single South African distributor, DISA Life Sciences. Management highlights foreign‑exchange impacts on comprehensive income and notes strategic goals to expand U.S. sales and pursue a potential future uplisting, while acknowledging risks from customer concentration, regulatory approvals, and a newly announced 30% U.S. tariff on South African imports.
Medinotec, Inc. reported mixed quarterly results driven by its distribution business and product development progress. The company recorded a $12,972 gain for the quarter ended August 31, 2025 compared with a $5,247 loss in the prior-year quarter, and a $2,819 loss for the six months ending August 31, 2025 versus a $9,399 loss a year earlier, showing narrower losses year-to-date. Revenue concentration remains high: 93% of total revenue for the quarter came from a single distributor in South Africa (up from 89%).
Cash and equivalents stood at $2,248,095 at August 31, 2025 (previously $2,769,686 on February 28, 2025), with $1,830,216 held in the U.S. The company has 11,755,548 common shares outstanding. Product milestones include FDA clearance for the OutFlo Aortic Valve Dilatation Balloon Catheter on March 11, 2025 with a planned U.S. launch in the fourth quarter of this financial year; several other catheter 510(k) submissions and CE/MDR processes remain in progress.